SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
- HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidermia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. Dressman, James; Kincer, Jeanie; Matveev, Sergey V.; Guo, Ling; Greenberg, Richard N.; Guerin, Theresa; Meade, David; Xiang-An Li; Weifei Zhu; Uittenbogaard, Annette; Wilson, Melinda E.; Smart, Eric J. // Journal of Clinical Investigation;2/1/2003, Vol. 111 Issue 3, p389
Presents a study which revealed that protease inhibitors contribute to the formation of atherosclerosis by promoting the upregulation of CD36-blocking antibodies and the subsequent accumulation of sterol in macrophages. Methods; Results; Discussion.
- PRELIMINARY PHARMACOKINETIC DATA ON ABT-378 ENCOURAGING. // AIDS Patient Care & STDs;Feb1998, Vol. 12 Issue 2, p146
Presents information on ABT-378, the next-generation protease inhibitor which when combined with small amounts of ritonavir (Norvir) has high drug concentrations which can suppressive human immunodeficiency virus-1 (HIV-1). Results of the study which examined three groups of volunteers who used...
- DATA IN FROM FIRST HEAD-TO-HEAD PROTEASE INHIBITOR. // AIDS Patient Care & STDs;Apr98, Vol. 12 Issue 4, p317
Presents information on a study which compared two protease inhibitors, Crixivan and Fortovas. Methodology used in the study; What happens when one of these inhibitors are used with azidothymidine (AZT) and 3TC; Information on the development of Fortovas.
- Saquinavir Study Results. // AIDS Patient Care & STDs;Sep98, Vol. 12 Issue 9, p720
Evaluates the results of a study conducted to assess the twice daily (BID) protease inhibitor regimens of saquinavir. What results of the study suggest; Comparison between BID dosing of SAQ and a SAQ dosing in a three-times daily regimen; Relation between the virologic response of each regimen.
- Decreased viral load. Rogers, Katie // Drug Topics;2/19/96, Vol. 140 Issue 4, p52
Focuses on the impact of indinavir, a protease inhibitor, on viral levels of HIV. Reduction of viral load; Preliminary study results of a phase II trial.
- Study shows use of combination treatment can curb spread of HIV. // New York Amsterdam News;03/08/97, Vol. 88 Issue 10, p16
Presents information on a study known as ACTG320, which was designed to determine the safety of the protease inhibitor indinavir, when given in combination with sidovudine (ZDV) and lamivudine (3TC), as compared to ADV plus 3TC. Sponsors of the study; Detailed information on the results of the...
- Review of protease inhibitor for use in HIV-1 infection. Huffman, Grace Brooke // American Family Physician;6/1/1997, Vol. 55 Issue 8, p2825
Presents a summary of the article `Human Immunodeficiency Virus-1 Protease Inhibitor. A Review for Clinicians,' by S.G. Deeks, et al from the `Journal of American Medical Association' dated 1997. Effect of protease inhibitor; Cost ranges of the drugs.
- Cell-based Assay for Testing Susceptibility of HIV-1 to Protease Inhibitors. Nogueira, Rita; Coelho, Sofia; Gon�alves, Jo�o // Retrovirology;2005 Supplement 1, Vol. 2, pP140
An abstract of the article "Cell-based Assay for Testing Susceptibility of HIV-1 to Protease Inhibitors," by Rita Nogueira, Sofia Coelho and Jo�o Gon�alves is presented.
- Diabetes, protease-inhibitor link unproved: directorate. // CMAJ: Canadian Medical Association Journal;09/01/97, Vol. 157 Issue 5, p502
States that the Therapeutic Drugs Directorate at Health Canada find no conclusive evidence to support a causal relationship between protease inhibitors and diabetes or hyperglycemia in HIV-infected patients.